STAT+: Pharmalittle: We’re reading about a setback for Pfizer, a boost for Novo Nordisk, and much more
Written by
STAT News
Published
0
comments
0
min
An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and older